Andera Partners Commits to Tubulis' €308 Million Series C for ADC Development

Andera Partners has reaffirmed its support for Tubulis by participating in a €308 million Series C financing round. This investment aims to bolster the clinical development of Tubulis' lead candidate TUB-040, an antibody-drug conjugate (ADC), and to expand the company’s innovative platform. Venrock Healthcare Capital Partners led the round, which included investments from Wellington Management and Ascenta Capital, alongside existing backers.

The funds will enable Tubulis to further investigate TUB-040, particularly for its application in ovarian cancer and lung adenocarcinomas. Currently assessed in a Phase I/IIa study, TUB-040 has received Fast Track designation from the U.S. FDA. The financing also supports the advancement of Tubulis' overall pipeline, ensuring ongoing innovation in ADC technology.

This €361 million investment marks the largest Series C funding for a European biotech firm and the highest for a private ADC developer worldwide. Andera Partner's previous participation in Tubulis' Series B round highlights its commitment to the company's growth and advancements in therapeutic solutions.